TYRATyra Biosciences, Inc.
Is it safe?
Mostly sound, with a caveat: insiders buying, but heavy debt (CCC) and big price swings.
Insiders were net buyers (+$20K, 90 days to Oct 8, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -83% · now 50% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TYRA take a bad year?
The deepest fall in TYRA's price history on file is −83%; it is 50% below its high today.
Worst drawdown on file · −50% today
- Cash runway
- 3.2 years
Cash runway · burning $27M a quarter at the current rate
- Annualised volatility
- 67%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $354M
- EBITDA, trailing twelve months
- −$160M
- Operating profit, trailing twelve months
- −$160M
- Annualised volatilitytwo years of daily moves
- 67%
- Worst drawdown on file
- −83%
- Below its 52-week high
- 50%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.